December 21, 2024

DealBook Column: A $25 Million Question Over a Bid for Dell

Dell did not want the bid by Michael Dell, the company founder, to be the only one in play.Ym Yik/European Pressphoto AgencyDell did not want the bid by Michael Dell, the company founder, to be the only one in play.

Is Stephen Schwarzman’s Blackstone Group really bidding for Dell? Or is it part of a bizarre, high-stakes charade?

That’s the question left lingering in the air in the wake of Dell’s 274-page proxy filing made late last week with the Securities and Exchange Commission about the continuing battle for the company.

Mr. Schwarzman’s firm submitted a letter two weeks ago asserting that it planned to pursue a formal bid for Dell worth at least $14.25 a share, more than the $13.65 offer that Dell’s board had already agreed to accept from Michael Dell, the company’s founder, and Silver Lake Partners.

DealBook Column
View all posts


To avoid the appearance of a conflict of interest given Mr. Dell’s insider status, the company’s board was given 45 days to continue to shop the company in hopes of finding a better offer. And, indeed, the appearance of a conflict of interest for Mr. Dell has become the running narrative. The cover of Barron’s over the weekend featured a cartoon of Mr. Dell running away with a laptop under his arm, suggesting he was trying to steal the company, with the headline: “Not So Fast, Michael.”

But over the last 45 days, virtually no competing bidders emerged, suggesting perhaps that nobody thought Dell was such a steal after all. It wasn’t for lack of trying. Evercore Partners, the investment bank, was offered an incentive payment of $30 million if it could complete a deal for Dell at a higher price. According to Dell’s proxy, Evercore contacted “67 parties, including 19 strategic parties, 18 financial sponsors and 30 other parties.”

Most were not interested. And then Blackstone arrived.

What did Mr. Schwarzman see that all of the other prospective bidders must have missed? That remains a mystery.

But what Mr. Schwarzman did next, thanks to Dell’s disclosure, may go a long way toward explaining what’s truly going on: Blackstone told Dell that it would not even consider bidding for the company unless Dell offered to pay the firm’s expenses, up to a whopping $25 million.

Yes, you read that correctly. Blackstone demanded that Dell pay it to go through the motions of bidding.

Here it is in the proxy: “The Blackstone consortium informed the special committee that it was not willing to proceed with its evaluation of the transaction contemplated” unless “it received an agreement from the company to reimburse the Blackstone consortium’s out-of-pocket expenses in connection with its evaluation of a possible transaction.”

Here’s what’s not in the proxy: Originally, Blackstone did not demand to be reimbursed for just out-of-pocket expenses — for consultants, travel and the like — but also sought to be able to receive payments for the time of its own executives, according to people involved in the process. Just think about it: How much would Mr. Schwarzman bill for his time? $10,000 an hour?

Ultimately, Dell’s special committee agreed to pay Blackstone’s out-of-pocket expenses but not hourly fees or contingency fees for its banking advisers. (By the way, the special committee also agreed to pay Silver Lake the same reimbursement to make the process fair.)

The fact that Blackstone refused to bid unless its costs were covered by Dell — a highly unusual maneuver — just goes to show you how little confidence it has that it expects to submit a winning bid for Dell.

Blackstone also required Dell to indemnify the firm from any lawsuits stemming from its involvement in the auction process, according to Dell’s documents.

For Dell’s special committee, agreeing to these bold demands from Blackstone is probably good business. If the board can keep a second bidder at the table, even if the suitor never makes a firm bid, Dell’s special committee will have insulated itself from criticism that it did not run a competitive process.

The real question is why, despite the $25 million reimbursement guarantee, Blackstone is risking its reputation to even contemplate a deal for Dell.

If Blackstone makes a formal bid — and so far it has not lined up financing — it will most likely be competing against a bid from Mr. Dell. While Blackstone has clearly been invited into the auction process, if Mr. Dell quits or is ousted as a result of a winning bid from Blackstone, the firm will appear to have made a hostile bid. Private equity firms have spent the last 25 years avoiding anything that could make them perceived as hostile because they typically want management teams to want to do business with them.

Last week, two Blackstone partners, Chinh Chu and David Johnson, who recently defected from Dell, met with Mr. Dell at his home. Mr. Dell is said to be open to working with Blackstone if they can agree on strategy, operations and corporate governance.

But by the looks of it, Blackstone and Mr. Dell are coming to the table from entirely different angles. Mr. Dell wants to keep the company intact and reinvest in developing the personal computer, tablet and emerging-market business. Blackstone’s strategy appears to center on selling Dell’s financing arm — it received some interest from GE Capital — and focusing on its services business.

What happens if Mr. Dell comes out with the following statement? “Unfortunately, after holding talks with Blackstone in good faith, I can’t participate in their transaction because of a disagreement over strategy. Their plan is a short-term and shortsighted effort to break up the company and put in peril Dell’s more than 100,000 employees.”

All of sudden, Blackstone would look like a barbarian at the gate in a big and very public nasty battle. (Some would claim Mr. Dell was being selfish, but the damage would be done — to Blackstone.)

Alternatively, is it really possible Blackstone would try to embrace Mr. Dell and make him the chief executive — which they have said they are open to doing? Blackstone has already been canvassing for other candidates. In fact, the firm contacted Mark Hurd of Oracle before ever even discussing the matter with Mr. Dell, which, of course, was a not-so-great way to ingratiate itself with a potential future partner.

And then there’s the ownership stakes. Mr. Dell owns about 15 percent of the equity in Dell. It is almost impossible to believe that Blackstone would put in more equity than Mr. Dell already has in the company. That would leave Blackstone as a smaller equity owner than Mr. Dell himself. Would Blackstone really team up with him and let him have control of the company?

All of these questions have no good answers. But for $25 million in reimbursed expenses, maybe they don’t need them.

Article source: http://dealbook.nytimes.com/2013/04/01/a-25-million-charade-over-a-bid-for-dell/?partner=rss&emc=rss

Prescriptions: F.D.A. Approves Cell Therapy for Wrinkles

Blood stem cells, as from a bone marrow transplant, are used to treat serious cancers. Therapies using other types of stem cells, mostly still experimental, are envisioned to help repair damaged organs and to treat scourges like diabetes and Parkinson’s disease.

But cell therapy can also have its more trivial applications, like smoothing wrinkles. The Food and Drug Administration late Tuesday approved a therapy that uses a person’s own skin cells to help improve the appearance of the smile lines that can extend from the bottom of the nose to the sides of the mouth.

The treatment, called laViv, was developed by Fibrocell Science of Exton, Pa. It involves taking a sample of skin cells called fibroblasts, which make collagen, from behind the person’s ear. The sample is sent to the company’s laboratory, where the fibroblasts are multiplied in cell culture, a process that takes 11 to 22 weeks.

The cells are then sent back to the doctor, who injects them into the smile lines, (or frown lines), which are technically known as nasolabial folds.

The treatment was evaluated in two clinical trials with a total of 421 patients in which participants received either three treatments with laViv or three treatments with an injection that did not contain the cells. Six months after the third treatment, both the patients and their doctors, neither of whom knew whether the treatment or control was given, assessed the results.

In one study, 57 percent of the patients who got laViv thought the appearance of their own wrinkles had significantly improved, while only 30 percent of those in the control group thought so, according to the drug’s label. In the other study, 45 percent of those who got the treatment and 18 percent of those who got the control thought the appearance had improved.

Their doctors were a bit more critical. They thought the wrinkles’ appearance improved significantly in only 33 percent of the patients who received LaViv in one study and 19 percent in the other. But those figures were still higher than the 7 percent improvement in both studies for the control group.

The most common side effect, occurring in two-thirds of patients, were injection site reactions including redness, bruising, swelling, pain and hemorrhage.

LaViv will compete with various dermal fillers. Fibrocell has not announced a price, but a spokeswoman said it was expected to be $1,000 to $2,000 to create the personalized cell bank, and then perhaps $300 to $500 for each of the three treatment sessions.

Lack of funding has hindered development of the treatment. The company pursuing it, once known as Isolagen, filed for bankruptcy protection in 2009, but emerged a few months later as FibroCell.

Fibrocell’s shares, traded on the OTC Bulletin Board, were up 11 cents to $1.27 at 1:54 p.m.

Article source: http://feeds.nytimes.com/click.phdo?i=ea7b61dbab9e0293c6773d73430541f9